Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 202615 Citations
Retatrutide is a triple-agonist peptide (GLP-1, GIP, glucagon) that produced 28.7% weight loss in Phase 3 at 68 weeks. Not yet FDA approved. Strongest clinical weight loss data of any drug tested to date, with liver fat reduction exceeding 80% in MASLD subgroups.
1mg · Weekly
Summary: Add 2mL BAC water to your 5mg vial. Draw to 40.0 units on a U-100 syringe for a 1mg dose. This vial will last 5 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 1mg | Weekly |
| Moderate | 4mg | Weekly |
| Aggressive | 8mg | Weekly |
Retatrutide dosing starts at 1 mg weekly regardless of prior GLP-1 experience. The triple-receptor mechanism means your gut is adapting to three agonists at once, not just one. Even users who tolerated tirzepatide at high doses report rougher GI onboarding with retatrutide. Reconstitution math for common vial sizes: a 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL. At that concentration, 1 mg equals 0.2 mL, which is 20 units on a standard 100-unit insulin syringe. A 4 mg dose would be 80 units. For the 12 mg maintenance dose, you'll want a 15 mg vial with 2 mL BAC water (7.5 mg/mL); 12 mg then equals 1.6 mL or 160 units. At 160 units, consider splitting across two injection sites to reduce volume discomfort. Track your resting heart rate from day one. The glucagon component raises energy expenditure, and HR is the clearest early signal of dose-dependent cardiovascular stress. If your resting pulse sits above 90 bpm for more than a week, hold the current dose before escalating. Evening injections let you sleep through peak nausea, which typically hits 4 to 8 hours post-injection.
Dosing based on Phase 2 dose-escalation trial: retatrutide in adults with obesity (NEJM 2023) — 23 published references.View all sources →
Cross-check your Retatrutide reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Retatrutide is a triple-agonist peptide (GLP-1, GIP, glucagon) that produced 28.7% weight loss in Phase 3 at 68 weeks. Not yet FDA approved. Strongest clinical weight loss data of any drug tested to date, with liver fat reduction exceeding 80% in MASLD subgroups.